| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5520982 | Drug Discovery Today | 2017 | 7 Pages |
â¢Different people can respond differently to similar drug treatment regimes.â¢The risk of adverse drug reactions can also vary between individuals.â¢Stratified medicine uses this variation to identify appropriate treatments.â¢Potential effects of variability need to be considered at the start of studies.â¢Definitions of variability, and methods to assess it, require standardisation.
The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.
